Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular-targeting therapies against quantitative abnormalities in gene expression with malignant tumors.

Cancer science - 1 Apr 2017

Sakai Toshiyuki, Sowa Yoshihiro

Abstract excerpt

Genetic mutations in exons of oncogenes and tumor-suppressor genes causing qualitative abnormalities result in activation of the oncogenes and inactivation of the tumor-suppressor genes, thereby causing cancer. In contrast, we have previously demonstrated that decreases in the RB promoter activity by genetic or epigenetic abnormalities can also cause carcinogenesis. In addition, activation and inactivation of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Genetic

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Tumor Burden

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 28178388
DOI: 10.1111/cas.13188
PMCID: PMC5406604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular-targeting therapies against quantitative abnormalities in gene expression with malignant tumors.PMID 28178388Read ↗

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Semantic proximity Read ↗

Targeting the RB-pathway in Cancer TherapySemantic proximity Read ↗

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Semantic proximity Read ↗

Tumor Milieu Controlled by RB Tumor SuppressorSemantic proximity Read ↗

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.Semantic proximity Read ↗

Pan-cancer molecular analysis of the RB tumor suppressor pathwaySemantic proximity Read ↗

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.Semantic proximity Read ↗

Novel strategies for therapeutic design in molecular oncology using gene expression profiles.Semantic proximity Read ↗

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic StrategiesSemantic proximity Read ↗

An in vivo screening system to identify tumorigenic genes.Semantic proximity Read ↗

"RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist).Semantic proximity Read ↗

Targeting RB1 Loss in CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.